Intellia Therapeutics (NTLA) - Cash per Share

Symbol and logo of brand intelliatx.com (NTLA)

Cash per share dynamics for Intellia Therapeutics (NTLA) correlate with the progress of CRISPR drug trials and strategic alliances, with the latest figure standing at 3.39. However, high R&D costs and uncertainty regarding side effects are creating financial pressure. Looking ahead, FDA approval of in vivo therapy would allow the company to generate superprofits without requiring capital expenditures for manufacturing plants.

NTLA (Intellia Therapeutics) Cash per Share history from 07/04/2022 to 11/20/2026

Analytical breakdowns for Intellia Therapeutics (NTLA)

- cash and cash flow data:
Summary company analysis:Intellia Therapeutics
Core merchandise of Intellia Corp

For genome editing pioneer Intellia Therapeutics (NTLA), this metric reflects the amount of liquid assets per common share, which determines the financial runway for costly CRISPR developments. By analyzing the cash per share trend, an investor assesses the company's actual cash cushion, which protects capital from volatility and confirms the issuer's ability to fund innovative therapies without the urgent need to raise external capital.

Key competitors

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Stoke Therapeutics|Cash Funds per Share BioLife Solutions BLFS|Wave Life Sciences (WVE) - Cash on Hand per Share|Maze Therapeutics, Inc. - Cash per Share|Cash Funds Calculated per Share Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Cash Funds per Share|TSHA: Cash Calculated per Single Share|Cash Funds per Share uniQure Pharma|MGTX - Cash Funds Volume per Share|Cash per Share RGNX|Cash Funds per Share SLDB (Solid Biosciences)|Ocugen Corp - Cash per Single Share|PACB: Cash Funds per Single Share|benitec.com - Cash per Share|DSGN - Cash per Share|RCKT: Cash per Share|FDMT (4D Molecular Therapeutics Inc) - Cash Funds per Share|Cash per Single Share LXEO|Cash Funds per Share KRRO|Cash per Share EDIT|SLN - Cash on Hand per Share|Cash per Share PRQR (ProQR)|CDXS - Cash per Single Share|Sangamo Therapeutics Inc. - Cash per Share|NAUT - Cash per Share|MGX: Cash per Share|Cash per Single Share Precision BioSciences, Inc.|GBIO (Generation Bio) - Cash per Share|Boundless Bio Inc. (BOLD) - Cash Funds Calculated per Share|Cash per Single Share XCUR (exicuretx.com)|Imunon Inc - Cash Funds per Single Share|Cash per Share PHIO (Phio Pharmaceuticals Corp)|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology